Statement on combined hormonal contraceptives containing third or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

Bitzer, Johannes; Amy, Jean-Jacques; Beerthuizen, Rob; Birkhäuser, Martin; Bombas, Teresa; Creinin, Mitchell; Darney, Philip D; Vicente, Lisa Ferreira

http://hdl.handle.net/10400.26/9916

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Statement_on_combined_hormonal_contracetives.pdf		92.69 KB	Adobe PDF	Download

Send Feedback

Authors

Vicente, Lisa Ferreira

Abstract(s)

The controversy around the combined hormonal contraceptives (CHCs) of the so-called third (containing gestodene or desogestrel) and fourth generation (containing drospirenone, DRSP) has reached a highly emotional political dimension in which all those who are professionally responsible for women’s health are involved: the national health authorities, the pharmaceutical companies, the professional organisations, the prescribers, the media and the public (i.e. the current or potential users of CHCs). The – initially scientific – controversy has now led to a public health dispute that culminated in the decision of the French authorities to withdraw the combination containing ethinylestradiol (EE) and cyproterone acetate (CPA) from the market. The potential impact of this measure, namely the loss of confidence in all CHCs, could be quite serious.